Opiant Pharmaceuticals, Inc.
Q4 2021 Earnings Call Transcript

Published:

  • Disclaimer*:
    This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.
  • Operator:
    00
  • Ben Atkins:
    00
  • Roger Crystal:
    2
  • Matt Ruth:
    14
  • David O'Toole:
    17
  • Operator:
    23
  • Brandon Folkes:
    24
  • Roger Crystal:
    25
  • Brandon Folkes:
    27
  • David O'Toole:
    28
  • Brandon Folkes:
    29
  • Roger Crystal:
    29
  • Brandon Folkes:
    30
  • Operator:
    30
  • Carl Byrnes:
    30
  • Roger Crystal:
    Carl, I'll jump in and then I’ll Matt continue that. It’s Roger here. Yeah, just to say, I mean our commercial plans is we're not going to provide significant detail around numbers at this point. I need to say that. When Matt was hired in initial commercial team he was doing a tremendous work in the pre-launch world. And then given our view of where we see the market opportunity at the moment, the balance in the public interest sector and the retail, again, we're going to be hiring shortly after towards approval and at approval in particular, but this is not like building out a huge sales force like most drugs out there and a lot of it is in and around government affairs activities. And I think that's where Matt has tremendous experience. But Matt, anything you want to add to that.
  • Matt Ruth:
    31
  • Carl Byrnes:
    32
  • Roger Crystal:
    33
  • Matt Ruth:
    33
  • Carl Byrnes:
    34
  • Operator:
    34
  • David Bautz:
    34
  • Roger Crystal:
    35
  • Matt Ruth:
    35
  • David Bautz:
    35
  • Matt Ruth:
    35
  • David Bautz:
    37
  • Roger Crystal:
    37
  • David Bautz:
    38
  • Operator:
    39
  • Carl Byrnes:
    39
  • David O'Toole:
    39
  • Carl Byrnes:
    40
  • David O'Toole:
    40
  • Carl Byrnes:
    41
  • Operator:
    41
  • Roger Crystal:
    41
  • Operator:
    41

Other Opiant Pharmaceuticals, Inc. earnings call transcripts: